“The best doctor gives the least medicines,” according to the scientist, Benjamin Franklin. In the 1700s, a patient only had one doctor and few medications available. Today, 67% of patients over the age of 60 consume five or more medications, including over-the-counter drugs and supplements. More doctors have implemented a new methodology to treating older Americans known as de-prescribing due to the rise of drug consumption, possible negative interactions, and increased risk of side effects.
America is home to just under 325 million people including a birth every 8 seconds, a death every 12 seconds and one international migrant every 28 seconds. At this moment, half of us have at least one chronic disease (40%), mental illness (18%) or drug/alcohol
As quality measurements define the Medicare space, quality is not as defined in the commercial markets. An area where PBMs do not have a concentrated focus is in medication management. Managing claims exposure means finding out why a pharmacy program is not controlling trend. One way to manage trend is to take an active role in monitoring and managing drug adherence and drug interactions that have a direct relation to the trend and the total rewards strategy.
A new government study published in the October issues of the Medical Care journal examines the economic toll of opioid abuse, including direct health care costs, lost productivity and expenses to the criminal justice system. The study did not take into account the reduced quality
Polypharmacy is usually defined as 1.) the simultaneous use of multiple drugs to treat a single ailment or condition or 2.) the simultaneous use of multiple drugs by a single patient, for one or more conditions, which is most common between the ages of 62 and 85. Geriatricians and researchers have consistently warned prescribers and patients of the hazards of polypharmacy, yet it continues to increase in all age groups – particularly in seniors.
Recently, the maker of EpiPen found itself guilty in the court of public opinion for unjustifiably raising the costs of the life-saving drug by 600 percent for people who suffer from severe allergies. Today, Valeant Pharmaceuticals, the makers of an intravenous treatment used to treat